fashion -WSS

fashion

author：explore 2025-09-28 00:48:10 - browse：9

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

WSS

Biotech lab space demand falls sharply

How Vertex's cystic fibrosis drug is changing patients' lives

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

It's been 20 years since Dolly the sheep. Where's my clone?

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical student insurance fails on mental health care coverage

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Guidelines to prevent youth baseball injuries need more muscle

Senate HELP committee spars over health care workforce policies

Medical records are filled with copy

CommonSpirit Health keeps growing, even as it loses money

Malaria cases in Florida and Texas: Here’s what you need to know

Experts study whether long Covid risk adds up with each reinfection

Heart attack and stroke risk calculators need revising

Why are Kaiser Permanente staff considering a strike?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Lasker Awards 2023: Winners in biomedical research

Wikipedia

Emergency workers more likely to restrain Black patients: study

EpiPen alternative approval delay highlights citizen petition issue

It's been 20 years since Dolly the sheep. Where's my clone?

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Biotech lab space demand falls sharply

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

hotspot

focus

Wikipedia